Dediabetes Logo
Centro de evidencia
Descubre que funciona
Evidence Explorer
Busca en el grafo completo de evidencia
Investigacion reciente
Estudios mas recientes
Que cambio
Inteligencia semanal
Configuracion
Entrar / Unirse
Resumen de Investigación
Analyzed using Evidence Intelligence™

Semaglutide reduces cardiovascular risks in type 2 diabetes with CKD

Desarrollado con el marco Evidence Intelligence™ de Dediabetes

Última actualización 6 de julio de 2026

Key finding

Semaglutide reduced CV death/MI/stroke by 18% [hazard ratio (HR) 0.82 (95% confidence interval 0.68–0.98); P = .03]

The FLOW trial investigated the effects of semaglutide on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease, revealing significant reductions in cardiovascular death, myocardial infarction, and stroke.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Long-Term (1–5 y)

Risk of bias

Some Concerns

Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

The FLOW trial investigated the effects of semaglutide on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease, revealing significant reductions in cardiovascular death, myocardial infarction, and stroke.

Clinical relevance

The findings from the FLOW trial are clinically significant as they highlight the potential of semaglutide to improve cardiovascular outcomes in a vulnerable population. Patients with type 2 diabetes and chronic kidney disease are at increased risk for cardiovascular events, and effective interventions like semaglutide could lead to better health outcomes and reduced mortality rates in this group.

Keep in mind

The study's effectiveness data were unclear for some outcomes. Results may not be generalizable to populations outside the trial. Potential unmeasured confounders may affect the outcomes. The trial design may limit long-term outcome assessments.

Published in

Referencia de la Revista

Publication details and source links for this paper.

Kenneth WM, Katherine RT, Mustafa A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Chronic Kidney Disease: Results from the FLOW Trial. European Heart Journal. 2025;46(12):1096-1108. doi:10.1093/eurheartj/ehae613

View DOIView on PubMedView on PMC

Efectos Principales

Semaglutide reduced the composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke by 18% (HR 0.82, p = 0.03).

All-cause mortality was reduced by 20% with semaglutide (HR 0.80, p = 0.01).

No significant difference was observed in the composite outcome between groups (p = 0.03).

No significant difference was found in all-cause mortality between groups (p = 0.01).

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Semaglutide and All-cause mortality, Composite of CV death, non-fatal myocardial infarction, or non-fatal stroke.

This study contributes evidence to

Intervention

Semaglutide

Outcome

All-cause mortality

Evidence topic

Cardiovascular Risk

Primary intervention

Semaglutide

Primary outcomes

  • All-cause mortality
  • Composite of CV death, non-fatal myocardial infarction, or non-fatal stroke

Evidence topics

Cardiovascular RiskGLP-1 Receptor Agonists

Primary intervention

Semaglutide

Primary outcomes

All-cause mortalityComposite of CV death, non-fatal myocardial infarction, or non-fatal stroke

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

2
Evidence pairs
2
Relationships
2
Evidence topics
contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 60

2

Related topics

2

Evidence pairs

106

Related studies

High relevance in at least one topic

Why it is useful

  • Contributes to 2 evidence relationships
  • Includes primary outcome data
  • Linked to 2 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Agrega evidencia relacionada a tu Evidence Tracker

Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.

Evidencia principal

Relación de evidencia

GLP-1 Receptor Agonists and Cardiovascular Outcomes

Evidencia relacionada

Tema de evidencia

Cardiovascular Risk

Guardar evidencia

Tema de evidencia

GLP-1 Receptor Agonists

Guardar evidencia

Core evidence

Study findings

The primary outcomes reported in this study.

All-cause mortality

Semaglutide → All-cause mortality

Semaglutide → All-cause mortality

Evidence Intelligence™
EvidenceScore™
83
Strong
ImpactScore™
67
Slightly Positive
ConsistencyScore™
35
mixed
Estudios de apoyo: Basado en 6 estudios
Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

evidence suggest

La Evidencia Sugiere

  • Semaglutide significantly reduced cardiovascular events by 18% (HR 0.82).
  • All-cause mortality was reduced by 20% (HR 0.80).
  • No significant differences were found for some outcomes.
who this applies

A quién se aplica

  • Adults with type 2 diabetes.
  • Patients with chronic kidney disease.
  • Individuals at high risk for cardiovascular events.
keep in mind

Tener en Cuenta

  • Results are based on a specific population and may not apply to all patients.
  • The study's design may have limitations affecting the interpretation of results.
  • Further research is needed to confirm long-term benefits and safety.
between the lines

Entre Líneas

  • The study's effectiveness data were unclear for some outcomes.
  • Results may not be generalizable to populations outside the trial.
  • Potential unmeasured confounders may affect the outcomes.
  • The trial design may limit long-term outcome assessments.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

Desarrollado con el marco Evidence Intelligence™ de Dediabetes

This study contributes to evidence on GLP-1 Receptor Agonists and Cardiovascular Outcomes, GLP-1 Receptor Agonists and Cardiovascular Outcomes.

Relaciones de evidencia relacionadas

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Does GLP-1 Receptor Agonists improve cardiovascular outcomes?

Strong Evidence

GLP-1 Receptor Agonists may improve Cardiovascular Outcomes.

ConsistencyScore™: Results are mixed and should be interpreted cautiously.

Evidence caveat: The available evidence reports mixed findings.

Ranked evidence signals

  1. 1

    All-cause mortality

    EvidenceScore™ Strong | EvidenceScore™ 82.9 | weak positive | ConsistencyScore™ Mixed | 1 study

  2. 2

    Composite of CV death, non-fatal myocardial infarction, or non-fatal stroke

    EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study

Why this answer: This answer is cautious because the available studies report mixed findings.

Limitations

  • Population details are unavailable.
12 supporting studiesUpdated: Jul 2026
View Full Evidence
Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

Cardiovascular Risk Evidence HubGLP-1 Receptor Agonists Evidence Hub

Explore in Evidence Explorer

Open broader Evidence Explorer views for this relationship.

All studies on Semaglutide and All-cause mortalityAll studies on Semaglutide and Composite of CV death, non-fatal myocardial infarction, or non-fatal stroke

Related research

Read related research summaries.

Semaglutide may reduce cardiovascular events in non-diabetic patients.Oral semaglutide reduces cardiovascular events in type 2 diabetesHigher semaglutide doses improve glucose control in type 2 diabetesNovel Semaglutide Injection Shows Non-Inferior Glycemic ControlOral semaglutide may improve cardiovascular event prevention in type 2 diabetes.

Sin anuncios. Sin rastreo.

Centrada en la evidencia, no en la publicidad.

Segura y privada

Tus datos siempre están protegidos.

Siempre al día

Se agregan nuevos estudios todos los días.